Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADME Study of Erdafitinib in Healthy Males
NCT02692677Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 2016
- Primary completion
- Aug 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of erdafitinib in urothelial carcinoma (UC), sponsored by Janssen Pharmaceutical. Primary endpoints: Maximum Observed Plasma Concentration, Time to Reach Maximum Observed Plasma Concentration and 6 more. Started Mar 2016; status: completed.
02
Drugs
erdafitinib
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT02692677.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02692677.